Want to see FR:ALMIB full AI Analyst Report?
Top Page
Amoeba SA
(ALMIB)
Select Model
Select Model
Rating:41Neutral
Price Target:
€0.70
▲(2.50% Upside)
Action:Reiterated
Date:07/18/26
The score is driven primarily by very weak financial performance (collapsed revenue, persistent losses, ongoing cash burn) and elevated balance-sheet fragility (negative equity with higher debt). Technicals add further pressure given bearish moving-average alignment and negative momentum indicators, while valuation is constrained by loss-making earnings and no dividend support.
Positive Factors
Biological agriculture platform
The Willaertia magna platform gives Amoéba a defined technology base in biocontrol and biofertilizer applications. Demand for biological alternatives could support long-term relevance in agriculture, provided the company converts its platform into approved, scalable products.
Negative Factors
Revenue collapse
Revenue collapsing to effectively zero demonstrates that the business has not yet established dependable commercial traction. Without recurring sales, the company cannot spread fixed development and operating costs over a meaningful base, leaving future growth highly dependent on successful product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Biological agriculture platform
The Willaertia magna platform gives Amoéba a defined technology base in biocontrol and biofertilizer applications. Demand for biological alternatives could support long-term relevance in agriculture, provided the company converts its platform into approved, scalable products.
Read all positive factors
Amoeba SA (ALMIB) vs. iShares MSCI France ETF (EWQ)
Market Cap
€48.61M
Dividend YieldN/A
Average Volume (3M)146.66K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue GrowthN/A
EPS Growth-2.77%
CountryFR
Employees23
SectorGeneral
Sector StrengthN/A
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,817,220
10 Day Avg. Volume143,442
30 Day Avg. Volume146,661
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Amoeba SA Business Overview & Revenue Model
Company Description
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying acr...
How the Company Makes Money
Amoéba makes money by developing, manufacturing (directly and/or via industrialization partners), and selling biological products derived from its Willaertia magna platform, primarily into agriculture. Key revenue streams include: (1) Sales of bio...
Amoeba SA Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 601.60K | 664.31K | 0.00 | 0.00 |
| Gross Profit | -2.57M | -805.57K | -1.71M | -1.01M | -858.95K |
| EBITDA | -7.20M | -5.38M | -13.74M | -5.35M | -5.01M |
| Net Income | -8.30M | -6.59M | -14.30M | -8.02M | -7.82M |
Balance Sheet | |||||
| Total Assets | 10.13M | 5.65M | 6.29M | 12.39M | 14.50M |
| Cash, Cash Equivalents and Short-Term Investments | 4.72M | 458.94K | 519.33K | 5.53M | 7.28M |
| Total Debt | 12.24M | 12.07M | 4.92M | 2.36M | 12.50M |
| Total Liabilities | 15.49M | 16.06M | 10.23M | 4.23M | 14.30M |
| Stockholders Equity | -5.36M | -10.41M | -3.94M | 8.16M | 213.68K |
Cash Flow | |||||
| Free Cash Flow | -7.42M | -4.78M | -12.59M | -5.71M | -6.05M |
| Operating Cash Flow | -6.13M | -4.22M | -6.50M | -5.40M | -5.90M |
| Investing Cash Flow | -1.30M | -2.01M | -2.81M | -212.13K | -140.65K |
| Financing Cash Flow | 11.69M | 6.16M | 4.30M | 3.87M | 4.98M |
Amoeba SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €56.63M | 18.44 | 13.43% | 0.80% | 8.98% | -11.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €79.28M | -10.39 | -101.20% | ― | 66.67% | 74.66% | |
47 Neutral | €2.40M | -0.95 | -1.63% | 2.07% | -4.08% | -112.93% | |
41 Neutral | €48.61M | -5.19 | 84.60% | ― | ― | -2.77% | |
41 Neutral | €39.31M | -1.38 | -59.61% | 8.69% | ― | ― |
* General Sector Average
FR:ALMIB
Amoeba SA
0.63
-0.34
-35.23%
FR:ALJXR
Archos
0.27
0.07
33.01%
FR:ALATA
Atari SA
21.30
-8.20
-27.81%
FR:ALCLA
Claranova SA
0.69
-0.89
-56.44%
FR:BIG
Bigben Interactive
0.13
-1.24
-90.45%
FR:COH
Coheris
9.96
1.28
14.69%
Amoeba SA Corporate Events
Amoéba and Koppert Extend Biofungicide Distribution Deal to 2031
Jul 23, 2026
Amoéba SA and its partner Koppert, a global leader in biological crop protection, have extended their distribution agreement for the biofungicide solution targeting vines and vegetable crops by one year, pushing the term to June 2031. The par...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.